SU5416 and Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer
Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
RATIONALE: SU5416 may stop the growth of kidney cancer by stopping blood flow to the tumor.
Interferon alfa-2b may interfere with the growth of the cancer cells. Combining interferon
alfa-2b with SU5416 may be an effective treatment for kidney cancer.
PURPOSE: Phase II trial to study the effectiveness of combining SU5416 and interferon alfa-2b
in treating patients who have unresectable or metastatic kidney cancer.